Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

2.

The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans.

Crooke ST, Baker BF, Pham NC, Hughes SG, Kwoh TJ, Cai D, Tsimikas S, Geary RS, Bhanot S.

Nucleic Acid Ther. 2018 Feb;28(1):10-22. doi: 10.1089/nat.2017.0693. Epub 2017 Nov 29.

3.

The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.

Crooke ST, Baker BF, Witztum JL, Kwoh TJ, Pham NC, Salgado N, McEvoy BW, Cheng W, Hughes SG, Bhanot S, Geary RS.

Nucleic Acid Ther. 2017 Jun;27(3):121-129. doi: 10.1089/nat.2016.0650. Epub 2017 Feb 1.

4.

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.

Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, Salgado N, Bui HH, Hart CE, Burel SA, Younis HS, Geary RS, Henry SP, Bhanot S.

Mol Ther. 2016 Oct;24(10):1771-1782. doi: 10.1038/mt.2016.136. Epub 2016 Jun 30.

5.

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, Trip MD, Stroes ES.

J Lipid Res. 2010 May;51(5):1057-62. doi: 10.1194/jlr.M002915. Epub 2009 Dec 14.

6.

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.

Fidias P, Pennell NA, Boral AL, Shapiro GI, Skarin AT, Eder JP Jr, Kwoh TJ, Geary RS, Johnson BE, Lynch TJ, Supko JG.

J Thorac Oncol. 2009 Sep;4(9):1156-62. doi: 10.1097/JTO.0b013e3181b2793f.

7.

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients.

McHutchison JG, Patel K, Pockros P, Nyberg L, Pianko S, Yu RZ, Dorr FA, Kwoh TJ.

J Hepatol. 2006 Jan;44(1):88-96. Epub 2005 Oct 25.

PMID:
16274834
8.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.

Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.

Invest New Drugs. 2005 Oct;23(5):467-77.

PMID:
16133798
10.

Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.

Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.

Curr Opin Mol Ther. 1999 Jun;1(3):372-85. Review.

PMID:
11713802
11.

A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.

Cunningham CC, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Johnston JF, Monia B, Nemunaitis J.

Cancer. 2001 Sep 1;92(5):1265-71.

PMID:
11571742
12.

Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ.

Clin Cancer Res. 2001 May;7(5):1214-20.

13.

A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J.

Clin Cancer Res. 2000 May;6(5):1626-31.

14.

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI.

Clin Cancer Res. 1999 Nov;5(11):3357-63.

15.

Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).

Stevenson JP, Yao KS, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ.

J Clin Oncol. 1999 Jul;17(7):2227-36.

PMID:
10561280
16.

Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.

Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG.

J Clin Oncol. 1999 Nov;17(11):3586-95.

PMID:
10550158
17.

Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.

Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC.

J Virol. 1994 May;68(5):2906-14.

18.
19.

Target amplification systems in nucleic acid-based diagnostic approaches.

Kwoh DY, Kwoh TJ.

Am Biotechnol Lab. 1990 Oct;8(13):14-25. Review.

PMID:
1370001
20.

Analysis of substrate specificity of the PaeR7 endonuclease: effect of base methylation on the kinetics of cleavage.

Ghosh SS, Obermiller PS, Kwoh TJ, Gingeras TR.

Nucleic Acids Res. 1990 Sep 11;18(17):5063-8.

21.

Introduction and expression of the bacterial PaeR7 restriction endonuclease gene in mouse cells containing the PaeR7 methylase.

Kwoh TJ, Obermiller PS, McCue AW, Kwoh DY, Sullivan SA, Gingeras TR.

Nucleic Acids Res. 1988 Dec 23;16(24):11489-506.

22.

Introduction and expression of the bacterial PaeR7 methylase gene in mammalian cells.

Kwoh TJ, Kwoh DY, McCue AW, Davis GR, Patrick D, Gingeras TR.

Proc Natl Acad Sci U S A. 1986 Oct;83(20):7713-7.

24.

Mutational analysis of the cloned chicken thymidine kinase gene.

Kwoh TJ, Zipser D, Wigler M.

J Mol Appl Genet. 1983;2(2):191-200.

PMID:
6875426
25.

Stabilization of a degradable protein by its overexpression in Escherichia coli.

Cheng YS, Kwoh DY, Kwoh TJ, Soltvedt BC, Zipser D.

Gene. 1981 Jun-Jul;14(1-2):121-30.

PMID:
6266927
26.

Amino acid sequence of the precursor of rat liver alpha 2 micro-globulin.

Drickamer K, Kwoh TJ, Kurtz DT.

J Biol Chem. 1981 Apr 25;256(8):3634-6.

27.

In vitro and in vivo manipulations of bacteriophage Mu DNA: cloning of Mu ends and construction of mini-Mu's carrying selectable markers.

Chaconas G, de Bruijn FJ, Casadaban MJ, Lupski JR, Kwoh TJ, Harshey RM, DuBow MS, Bukhari AI.

Gene. 1981 Jan-Feb;13(1):37-46.

PMID:
6263754
28.

Examination of newly synthesized DNA in Escherichia coli.

Kwoh TJ, Chan PT, Patrick MH.

Mol Gen Genet. 1979 May 23;173(1):85-93. No abstract available.

PMID:
381843

Supplemental Content

Support Center